Torrent Pharmaceuticals Limited (TORNTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 2 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹5,122.8 ↑ 36.9% (1Y)

🎯 Key Takeaways

Torrent Pharmaceuticals is in a high-growth phase driven by strategic acquisitions and geographic expansion, particularly in Brazil, the US CDMO segment, and domestic markets. The company has transitioned from a domestic-focused player to a diversified, export-oriented pharmaceutical enterprise with strong top-line momentum and improving profitability metrics.
Revenue declined 2.8% QoQ to ₹2,809 in Q3FY25.
⚠️ Integration risks from the JB Pharma acquisition could materialize if synergies are not fully realized or if unexpected liabilities emerge.

Market Cap

₹1.49 L Cr

P/E Ratio

80.1

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About TORNTPHARM 📊 Interactive Charts

📖 The Story

Torrent Pharmaceuticals is in a high-growth phase driven by strategic acquisitions and geographic expansion, particularly in Brazil, the US CDMO segment, and domestic markets. The company has transitioned from a domestic-focused player to a diversified, export-oriented pharmaceutical enterprise with strong top-line momentum and improving profitability metrics.

📰 What's Happening

In Q1 FY27, Torrent reported record revenue of ₹4,921 crores (+55% YoY), fueled by organic growth and the JB Pharma acquisition, with EBITDA rising 61% to ₹1,664 crores and margins stable at 33.8%. The company also finalized the listing of shares from its amalgamation with JB Chemicals, effective 28 July 2026. Additionally, Shanti Ekambaram was appointed as an Additional Independent Director effective 30 July 2026, bringing deep finance and governance expertise. The board approved the Q1 results on 30 July 2026, highlighting regional momentum across India, Brazil, and the US.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	2,491	2,591	2,660	2,732	2,745	2,859	2,889	2,809
Operating Profit	736	825	851	924	914	928	923	947
OPM %	29.2%	30.5%	31.0%	31.8%	32.2%	31.6%	32.5%	32.5%
Net Profit	287	378	386	443	449	457	453	503
EPS	₹8.48	₹11.18	₹11.39	₹13.10	₹13.27	₹13.51	₹13.37	₹14.88

Revenue has grown consistently over the past four years, with a sharp acceleration in Q1 FY27 to ₹4,921 crores from ₹2,809 crores in Q3 FY25, reflecting the impact of the JB Pharma integration and expansion into high-growth markets like Brazil and the US CDMO segment. Operating margins have remained stable around 32-33%, indicating disciplined cost management despite scale. Net profit growth has been more measured, rising 3% YoY in Q1 FY27 to ₹566 crores, suggesting margin compression from exceptional items or integration costs. The company continues to demonstrate strong operational leverage, with EBITDA margins holding firm even as revenue growth accelerates.

🔮 Management Outlook & What's Next

Management emphasized sustained growth in key markets and financial resilience during the Q1 FY27 results announcement on 30 July 2026, though no specific future targets or deadlines were provided. The company highlighted the contribution of regional diversification and the JB Pharma acquisition to its performance, signaling confidence in continued momentum. No formal long-term guidance was disclosed, but the tone was cautiously optimistic regarding execution and market positioning.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB CIPLA DRREDDY LUPIN

⚠️ Risk Factors

1. Integration risks from the JB Pharma acquisition could materialize if synergies are not fully realized or if unexpected liabilities emerge. 2. Exposure to Brazil and US markets introduces currency and regulatory volatility, which management did not fully quantify in recent filings. 3. High valuation (P/E of 80.1) may limit upside if growth moderates or earnings guidance remains vague. 4. Dependence on a few key geographies for revenue growth creates concentration risk despite diversification efforts.

📋 Recent Filings

🧠 Analyst's Read

Torrent Pharmaceuticals is executing a clear expansion strategy with tangible results in revenue and margins, but the lack of formal forward guidance and elevated valuation warrant caution. Investors should monitor the pace of integration in Brazil and CDMO segments, as well as any updates on capital allocation or market-specific challenges in the coming quarters.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on TORNTPHARM

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TORNTPHARM files new disclosures

Track TORNTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TORNTPHARM — Free

Free account · 2 AI queries/day